Talk:David Zarling
![]() | This article was previously nominated for deletion. The result of the discussion was Consensus to keep. |
This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
![]() | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
|
Untitled
- I attended David Zarling's presentation at 5th annual cancer drugs R&D conference in Phoenix, Arizona (Feb 21-22). His new company has developed a set of drugs that hypothetically can help with even the latest stages of prostate cancer when it gets to the bone (6 months prognosis).
- I know about the diseases not only from textbooks and follow clinical trials of Synta and Cougar. Colby's drug candidates will probably have lower toxicity and higher efficacy then Synta's and Cougar's. I would like to enroll into early stage clinical prevention trials...
- I asked him for information on Colby, his scientists and himself, but since the company is in early stage, most of the data is confidential. He sent me his biography and I thought it would be worthwhile to put his profile onto Wikipedia.
- I work for GTCbio and volunteer at several institutions targeting diseases of aging. This article is not self promotion and any help with getting the message that Colby developed really potent prostate cancer therapeutics is much appreciated. There are many men that need hope.